Haemonetics Corporation
Rank #192HypergrowthHAE · NYSE · Healthcare
Haemonetics Corporation (HAE) — Rank #192 by gross profitability (GP/assets 0.33) · ROE 11.6% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0000313143 · all metrics point-in-time as of the filing date.
About
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions.
Show moreShow less
The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors.
The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- April 3
- Website
- haemonetics.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$4.78B
P/E (annual)
51.3
P/S (annual)
3.6
P/B
5.7
P/OCF (annual)
16.3
Shareholder Yield
9.6%
Employees
3,009
Industry
Medical Devices
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
7.1%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -9.6% — per-share value needs a total required return of -2.5% once share-count change is priced in.
vs. own 6-year median revenue growth: 7.6%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
2.8%
r = 10% (base)
7.1%
r = 12%
10.8%
Net debt / market cap: 19.1%
Note: current FCF margin is 1.6σ above its historical mean — implied growth may understate valuation risk if the margin reverts.
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Earnings bubble check
Current margins may be above sustainable levels — a P/E based on peak earnings can overstate cheapness.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.33
Primary signal (Novy-Marx).
13th of 17 SIC 3841 peers
Return on equity
11.6%
Gross margin
59.0%
14th of 17 SIC 3841 peers
Revenue growth (YoY)
42.1%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2012 | 2013 | 2014 | 2015 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
Earnings CAGR (3Y)
-5.5%
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.83
16th of 16 SIC 3841 peers (best = lowest)
Current ratio
3.08×
9th of 17 SIC 3841 peers
Quick ratio
1.67×
Net cash
-$950.77M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$260.44M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.68
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
2.5%
Stock-based comp intensity.
Piotroski F-Score
F-Score
7 / 9
Fundamental-strength score (0-9).